Bactiguard®

Handelsbanken Small & Mid Cap Seminar 2024

Wednesday 5 June 2024

Christine Lind, CEO




Opportunities behind critical global healthcare trends

The issues

- Antimicrobial resistance one of the top global public health threats facing humanity – associated with the death of close to 5 million people globally in 2019
- 1 in 10 patients worldwide affected by healthcare associated infections
- Demographic development, ageing population and increasing lifestyle diseases
- Political unrest, conflicts, wars and natural disasters
- Demand for more efficient and safe healthcare

The market opportunity (USD 80bn)



2

Well proven technology

Solid clinical evidence


- More than 100,000 patients included in clinical trials
- The efficacy assessed in more than 40 clinical studies
- Most recent RCT studies show 70% risk reduction of infection




How the technology works

Reduces microbial adhesion and biofilm formation

- **Biocompatible**, **safe** and **well-proven** to reduce the risk of device related infections
- Ultra-thin noble metal coating technology; gold, silver & palladium
- In contact with fluids, the noble metals create a galvanic effect due to their varying electro potentials




Fewer bacteria attach to a Bactiguard coated surface



A global MedTech company

Based on a Swedish innovation

- Company founded in 2005 the concept is almost a hundred years old
- Stems from the Swedish Nobel Prize laureate, Gustav Dahlén (AGA Lighthouse)
- Billy Södervall refined the technology in the 1970s applying it to medical devices
- Some 230 million coated foley catheters sold in the US, by our long-term license partner BD – zero adverse events reported related to the coating



"In 2023, we made the biggest strategic shift in Bactiguard's history"



The new, license focused Bactiguard

Purpose (why we exist)

"to champion a healthier world by preventing infections"

Vision (what we strive to be, visionary, long-term aspiration)

"to be the global standard of care for preventing medical device related infections"

Mission (what we do to reach our vision)

"by being the **premier partner for leading MedTech companies**, joining forces to **redefine healthcare** and **improve health** worldwide"



A knowledge and specialist organization

Strategic focus areas to achieve profitable and sustainable growth



R&D Medical and science Regulatory

Wound Management portfolio

Premier partner for global MedTech companies

- Enhance our partners' medical devices with advanced infection prevention technology to minimize the risk of device-related infections
- Tailor the coating manufacturing process to fit specific devices, ensuring safe and efficient large-scale production
- Our coating technology differentiates the license partners' medical devices





Strong collaboration with BD

In partnership since 1995 – longest and strongest

Recap

- Significant global market value for Foleys ~USD 1.5bn, annual growth ~5%*
- Exclusive global license for Bactiguard coated Foley catheters (ex China), agreement from December 2023
- Limited impact in 2024 but more substantial contribution over time

Recent highlights

- MDR-approval for coated silicone Foley catheters – supports BD's go-to-market strategy in Europe
- Participated BD Global Sales & Marketing Summit 2024 in New Jersey


 session on differentiation and value add to urology and critical care portfolios
- Transition process for additional markets for coated Foleys ongoing



11



Continued progress in Zimmer Biomet partnership



Recap

- Global leader in orthopedics
- Two agreements: trauma implants (2019) and multiple product segments (2022)
- "Let's talk about infections" theme 2023

Recent highlights

- European ZNN Bactiguard rollout continues – strong recognition and demand, slower uptake
- Japan launch of ZNN Bactiguard expected end of Q2

Wound Management by Bactiguard

- Manufacturing plant in Penang, Malaysia
- Latest technology and equipment
- High-quality medical devices
- Sales offices in Malaysia and India
- Sales representatives in Europe





Wound Management by Bactiguard

Preventing infections by offering effective, biocompatible solutions to improve healing

Offering includes


- **Hydrocyn aqua**, an innovative wound care product enabling wound healing and preventing infection
- A wide range of **surgical sutures** including specialist sutures for cardiovascular operations and eye operations



Key priorities ahead – 2024 characterized by transition

Seize USD 80 billion opportunity presented within five strategic therapeutic areas

- Current partnerships BD, Zimmer Biomet and Well Lead
- New partnerships in strategic therapeutic areas
- Stable profitability within Wound Management
- A knowledge and specialist organization
 - corporate culture
 - specialist areas (R&D, coating, medical, commercial, and regulatory)
- Profitable and sustainable growth for the new Bactiguard





to champion a healthier world by preventing infections